Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

INTRODUCTION: Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer. METHODS: Her-2-negative breast cancer patients with tumours large...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Quintela-Fandino, M, Urruticoechea, A, Guerra, J, Gil, M, Gonzalez-Martin, A, Marquez, R, Hernandez-Agudo, E, Rodriguez-Martin, C, Gil-Martin, M, Bratos, R, Escudero, M J, Vlassak, S, Hilberg, F, Colomer, R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453846/
https://ncbi.nlm.nih.gov/pubmed/25058346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.397
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados